Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Salesforce enters the week with a split picture: the stock is up 5.8% over the past five days to $238.01, yet short interest has quietly started climbing again after last week's sharp unwind, creating a tension worth watching ahead of the 2 December earnings date.
The positioning story has shifted in a meaningful way since the B of A upgrade note published Monday. Short interest fell 8.6% over the past week to 3.6% of free float, an unwind that tracked directly with the price rally. But the single-session data tells a different story: shorts added 1.7% on Tuesday alone, suggesting some sellers are rebuilding into strength rather than capitulating outright. The 30-day picture is the sharper angle. Short interest is up 42% over that window, roughly 10 million additional shares compared to mid-September levels, even after the recent covering. Borrow costs have risen 31% in a week to 0.49%, still low in absolute terms but a notable acceleration from the sub-0.2% readings seen earlier in October. Availability remains extremely loose at 2,836% of short interest, meaning there is no practical constraint on adding new shorts. Options positioning is broadly neutral: the put/call ratio at 0.96 is just below its 20-day average of 0.99, and the z-score of minus 0.55 puts it in unremarkable territory.
The Street is heavily skewed towards the bull case, but the nuances matter. With 34 buy ratings and just one underperform, the consensus is about as one-sided as it gets. The mean target of $285.68 implies roughly 20% upside from current levels. Bulls point to Agentforce and Data ARR of $3.9 billion, up 210% year on year, accelerating cRPO growth of 14% in Q2, and what the company describes as record pipeline levels. Bears counter that the AI monetisation narrative rests on products whose revenue contribution remains hard to verify, and that the company carries execution risk across a broad and aging portfolio. Valuation sits at a trailing P/E of 14.7 and EV/EBITDA near 10.2, both of which have drifted lower over the past 30 days as the stock underperformed on a one-month basis, down 3.9%. The ORTEX factor scores show a sharp divergence: the analyst recommendation differential ranks in the 97th percentile, while 30-day EPS momentum ranks in just the 17th, a gap between Street enthusiasm and near-term estimate momentum that is worth noting.
On the ownership side, the most recent institutional data shows BlackRock adding just over a million shares to a position already above 72 million, and Capital Research adding around 900,000. Harris Associates, a known value-oriented holder, added 1.2 million shares through August. Morgan Stanley, by contrast, trimmed by 7.7 million shares in the June quarter, the largest single reduction among top holders. Marc Benioff holds 22 million shares as of April, but insider activity in the SEC filings through September consisted entirely of option exercises followed by tax-withholding sales, with a net 90-day value of minus $173,000, routine compensation mechanics rather than a directional signal.
Retail attention is running elevated. The Wikipedia page-view z-score registered 1.84 against Salesforce's own 90-day history as of mid-September, a reading that reflects public interest following the B of A upgrade and the AI coverage cycle rather than any direct read on the business. Peer performance over the past week has been broadly positive for the enterprise software group: DOCU gained 6.0%, ASAN 6.1%, and TYL 4.8%, broadly in line with CRM's 5.8%. ADBE was the clear laggard, slipping 0.8%, while NOW barely moved at 0.5%.
The December earnings date is 49 days away. Between now and then, the key question is whether the short rebuild currently underway in daily estimates represents a fresh conviction bet against the AI narrative, or simply tactical hedgers fading the post-upgrade rally into an overbought setup.
See the live data behind this article on ORTEX.
Open CRM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
